232 related articles for article (PubMed ID: 38410247)
1. Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center's experience.
Živković SA; Lacomis D; Soman P
Front Cardiovasc Med; 2024; 11():1345608. PubMed ID: 38410247
[TBL] [Abstract][Full Text] [Related]
2. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
[TBL] [Abstract][Full Text] [Related]
4. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
Papagianni A; Ihne S; Zeller D; Morbach C; Üçeyler N; Sommer C
Amyloid; 2022 Mar; 29(1):14-22. PubMed ID: 34632904
[TBL] [Abstract][Full Text] [Related]
5. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey.
Nativi-Nicolau J; Siu A; Dispenzieri A; Maurer MS; Rapezzi C; Kristen AV; Garcia-Pavia P; LoRusso S; Waddington-Cruz M; Lairez O; Witteles R; Chapman D; Amass L; Grogan M;
JACC CardioOncol; 2021 Oct; 3(4):537-546. PubMed ID: 34729526
[TBL] [Abstract][Full Text] [Related]
6. Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.
Ungericht M; Wanschitz J; Kroiss AS; Röcken C; Schuetz T; Messner M; Zaruba MM; Loescher WN; Poelzl G
J Nucl Cardiol; 2023 Aug; 30(4):1420-1426. PubMed ID: 35581484
[TBL] [Abstract][Full Text] [Related]
7. Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review.
Aldinc E; Campbell C; Gustafsson F; Beveridge A; Macey R; Marr L; Summers C; Zhang D
BMC Musculoskelet Disord; 2023 Sep; 24(1):751. PubMed ID: 37740174
[TBL] [Abstract][Full Text] [Related]
8. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis.
Nakagawa M; Sekijima Y; Yazaki M; Tojo K; Yoshinaga T; Doden T; Koyama J; Yanagisawa S; Ikeda S
Amyloid; 2016; 23(1):58-63. PubMed ID: 26852880
[TBL] [Abstract][Full Text] [Related]
9. Transthyretin amyloidosis: Putting myopathy on the map.
Pinto MV; Milone M; Mauermann ML; Dyck PJB; Alhammad R; McPhail ED; Grogan M; Liewluck T
Muscle Nerve; 2020 Jan; 61(1):95-100. PubMed ID: 31587306
[TBL] [Abstract][Full Text] [Related]
10. [Neurological manifestations of ATTR amyloidosis].
Pernice HF; Hahn K
Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
[TBL] [Abstract][Full Text] [Related]
11. Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
Bézard M; Kharoubi M; Galat A; Poullot E; Guendouz S; Fanen P; Funalot B; Moktefi A; Lefaucheur JP; Abulizi M; Deux JF; Gendre T; Audard V; El Karoui K; Canoui-Poitrine F; Zaroui A; Itti E; Teiger E; Planté-Bordeneuve V; Oghina S; Damy T
Eur J Heart Fail; 2021 Feb; 23(2):264-274. PubMed ID: 33094885
[TBL] [Abstract][Full Text] [Related]
12. Wild-Type Transthyretin Cardiac Amyloidosis is Not Rare in Elderly Subjects: the CATCH Screening Study.
Aimo A; Vergaro G; Castiglione V; Fabiani I; Barison A; Gentile F; Ferrari Chen YF; Giorgetti A; Genovesi D; Buda G; Franzini M; Piepoli M; Moscardini S; Rapezzi C; Fontana M; Passino C; Emdin M
Eur J Prev Cardiol; 2024 Mar; ():. PubMed ID: 38456769
[TBL] [Abstract][Full Text] [Related]
13. A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey.
González-Moreno J; Losada-López I; Cisneros-Barroso E; Garcia-Pavia P; González-Costello J; Muñoz-Beamud F; Campistol JM; Fernandez-Torron R; Chapman D; Amass L
Neurol Ther; 2021 Dec; 10(2):833-845. PubMed ID: 34331265
[TBL] [Abstract][Full Text] [Related]
14. Multidisciplinary Approaches for Transthyretin Amyloidosis.
Koike H; Okumura T; Murohara T; Katsuno M
Cardiol Ther; 2021 Dec; 10(2):289-311. PubMed ID: 34089151
[TBL] [Abstract][Full Text] [Related]
15. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT.
Nativi-Nicolau J; Judge DP; Hoffman JE; Gundapaneni B; Keohane D; Sultan MB; Grogan M
ESC Heart Fail; 2021 Oct; 8(5):3875-3884. PubMed ID: 34432383
[TBL] [Abstract][Full Text] [Related]
16. Ultrastructure in Transthyretin Amyloidosis: From Pathophysiology to Therapeutic Insights.
Koike H; Katsuno M
Biomedicines; 2019 Feb; 7(1):. PubMed ID: 30764529
[TBL] [Abstract][Full Text] [Related]
17. Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS).
Ladefoged B; Clemmensen T; Dybro A; Hartig-Andreasen C; Kirkeby L; Gormsen LC; Bomholt P; Gillmore J; Poulsen SH
ESC Heart Fail; 2023 Feb; 10(1):234-244. PubMed ID: 36193570
[TBL] [Abstract][Full Text] [Related]
18. Familial occurrences of cardiac wild-type transthyretin amyloidosis: a case series.
Westin OM; Clemmensen TS; Hansen AT; Gustafsson F; Poulsen SH
Eur Heart J Case Rep; 2024 May; 8(5):ytae199. PubMed ID: 38765770
[TBL] [Abstract][Full Text] [Related]
19. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis.
Aus dem Siepen F; Hein S; Hofmann E; Nagel C; Schwarting SK; Hegenbart U; Schönland SO; Weiler M; Frey N; Kristen AV
J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673530
[No Abstract] [Full Text] [Related]
[Next] [New Search]
